Full Press Release Details
IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, November 4, 2025 to report its third quarter 2025 financial results and provide a corporate update.
Participants may access the webcasthere. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days.
About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY®(lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment ofDemodexblepharitis. Tarsus is also developing TP-04 as an ophthalmic gel for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease, all of which are in Phase 2.
| Media Contact: |
| Adrienne Kemp |
| Sr. Director, Corporate Communications |
| (949) 922-0801 |
| AKemp@tarsusrx.com |
| Investor Contact: |
| David Nakasone |
| Head of Investor Relations |
| (949) 620-3223 |
| DNakasone@tarsusrx.com |